Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

Supplements And Featured Publications, Updates in NRG1+ Tumors,

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Alison Schram, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase 1/2 eNRGy trial (NCT02912949), which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Findings from the eNRGy trial demonstrated a 29% overall response rate (ORR) with zenocutuzumab, an investigational bispecific antibody, in patients with locally advanced, unresectable or metastatic, NRG1 fusion–positive solid tumors. 

Confirmed partial responses (PRs) were observed in 42% of the 12 patients with NRG1 fusion–positive pancreatic ductal adenocarcinoma treated with the novel agent. An additional 50% of these patients derived stable disease from zenocutuzumab, Schram says. In this cohort, 100% of patients with elevated CA 19-9 measurements experienced a decline of more than 50%, Schram explains.

The ORR was 25% in the non–small cell lung cancer cohort (n = 24) and responses were observed irrespective of prior afatinib (Gilotrif) treatment, Schram says. In the basket cohort, one patient each with breast cancer and cholangiocarcinoma derived a PR, yielding a confirmed ORR of 22% in this cohort (n = 9), Schram says.

Notably, 40% of patients had treatment ongoing at the time of the data cut-off, Schram says. As such, zenocutuzumab could offer patients with heavily pretreated NRG1 fusion–positive solid tumors an effective treatment option, concludes Schram.